与高风险乳腺癌患者相关的生物学相关性,使用计算方法确定
Jung Hun Oh1, Fresia Pareja2, Rena Elkin3
1Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ohj@mskcc.org.
NPJ breast cancer
|January 28, 2025
概括
一种新的无监督方法确定了一个高风险的乳腺癌群体. 这个群体显示高低氧基因激活和较少的瘤透淋巴细胞 (TILs),表明一个独特的,预后不佳的生物特征.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 一个先前确定的乳腺癌亚组表现出不良的预后.
- 描述这种高风险群体的生物驱动因素对于了解疾病进展至关重要.
研究的目的:
- 阐明高风险乳腺癌小组的独特生物学特征.
- 为了研究缺氧和免疫细胞透在这个子组中的作用.
主要方法:
- 使用新的无监督方法整合多原子数据.
- 对缺氧信号和免疫细胞组成的分析 (CIBERSORT,白细胞分数).
- 评估PAM50亚型内的瘤透淋巴细胞 (TILs) 的空间分数.
主要成果:
- 高风险组在三个特征上显示出显著更高的缺氧得分 (p < 0.0001).
- 在高风险和低风险组之间观察到免疫细胞组成的显著差异.
- 在基底亚型中,低风险组与高风险组相比,TIL的空间分数较高 (p = 0.0362).
结论:
- 预后不佳的乳腺癌亚组的特征是高低氧相关基因激活.
- 瘤透淋巴细胞 (TILs) 的数量较少与这种高危人群有关.
- 这些发现突出了独特的生物特征,导致乳腺癌小组的预后不佳.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
06:06High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
497
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Actuarial Approach
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
